Thyroid Ablation Devices Market Growth & Trends

The global thyroid ablation devices market size is expected to reach USD 460.5 million by 2030, registering a CAGR of 13.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The availability of advanced treatment methods and the increasing prevalence of thyroid cancer is anticipated to augment the overall industry growth Commercialization & ongoing developments for technologically advanced thyroid ablation systems, and proven clinical efficacy is expected to favor the product demand. The ease of treatment, compared to other surgical procedures, is anticipated to boost the growth. Rising awareness about the benefits of thyroid ablation and an increasing number of thyroid cancer patients for surgical cancer treatment is predicted to foster the product demand.

Minimally invasive surgery is gaining popularity over traditional surgery due to various associated advantages, such as the need for a smaller incision, reduced pain, faster recovery time, and minimal scarring. In addition, in some instances, minimally invasive surgery is considered more accurate than traditional surgery. Minimally invasive procedures reduce hospital stays, which, in turn, helps in saving extra costs associated with the treatment. Increasing cases of thyroid cancer across the globe are predicted to contribute to industry growth. For instance, as per the American Cancer Society, around 43,720 new cases of thyroid cancer were observed in the U.S. This cancer is about 3 times more common in women than men, creating a high product demand among women.

Thyroid Ablation Devices Market Report Highlights

  • The Radiofrequency Ablation (RFA) segment held the largest revenue share in 2022 owing to a surge in the adoption of RFA devices due to better efficiency
  • The thermal-based devices segment held the largest revenue share in 2022 as these devices significantly decrease intraoperative blood loss and shorten the operational time
  • The thyroid cancer application segment is anticipated to gain the highest market share by 2030 due to the rising number of thyroid-related cancer cases across the globe
  • The North America region led the industry in 2022 owing to the high product demand for the treatment of various thyroid diseases
  • Asia Pacific is anticipated to exhibit the fastest CAGR from 2023 to 2030 owing to the rising adoption of minimally invasive surgeries across several countries in Asia